Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
RESEARCH TOOLSreports
Holding MRVI?
Track your performance easily
MRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.52 - $11.56
Previous Close$9.24
Volume1.28M
Average Volume (3M)2.40M
Market Cap
$2.33B
Enterprise Value$2.65B
Total Cash (Recent Filing)$573.17M
Total Debt (Recent Filing)$554.76M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 06, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding252,237,419
10 Day Avg. Volume1,815,981
30 Day Avg. Volume2,398,491
Standard Deviation0.17
R-Squared0.00
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)5.34
Price to Sales (P/S)8.28
Price to Cash Flow (P/CF)30.40
P/FCF Ratio26.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.52
Enterprise Value/Gross Profit18.91
Enterprise Value/Ebitda88.10
Forecast
1Y Price Target
$11.00Price Target Upside20.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Maravai Lifesciences Holdings News
Bulls Say, Bears Say
Bulls Say
CollaborationsNew Hopkins collaboration on mRNA Innovation Center should further drive adoption over time.
Growth DriversFieldwork and company-specific growth drivers increase the likelihood that Maravai could accelerate to double-digit top-line growth in 2025.
Product DemandGrowth was driven by higher demand for CleanCap analogs, GMP mRNA, and Glen Research products.
Bears Say
EarningsAdjusted EBITDA was below the model and the 2024 adjusted EBITDA outlook was lowered, though 2024 revenue guidance was maintained.
Financial PerformanceEBITDA misses again on mix, startup costs, and R&D/collaboration investments.
RevenueBiologics Safety Testing fell approximately 5% year-over-year and 18% quarter-over-quarter, with the revenue shortfall attributed to disappointing China performance.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MRVI FAQ
What was Maravai Lifesciences Holdings’s price range in the past 12 months?
Maravai Lifesciences Holdings lowest stock price was $4.52 and its highest was $11.55 in the past 12 months.
What is Maravai Lifesciences Holdings’s market cap?
Currently, no data Available
When is Maravai Lifesciences Holdings’s upcoming earnings report date?
Maravai Lifesciences Holdings’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Maravai Lifesciences Holdings’s earnings last quarter?
Maravai Lifesciences Holdings released its earnings results on Aug 07, 2024. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.001.
Is Maravai Lifesciences Holdings overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings’s price is currently Undervalued.
Does Maravai Lifesciences Holdings pay dividends?
Maravai Lifesciences Holdings does not currently pay dividends.
What is Maravai Lifesciences Holdings’s EPS estimate?
Maravai Lifesciences Holdings’s EPS estimate is >-$0.01.
How many shares outstanding does Maravai Lifesciences Holdings have?
Maravai Lifesciences Holdings has 141,553,340 shares outstanding.
What happened to Maravai Lifesciences Holdings’s price movement after its last earnings report?
Maravai Lifesciences Holdings reported an EPS of $0 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -6.813%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings?
Among the largest hedge funds holding Maravai Lifesciences Holdings’s share is Gotham Asset Management LLC. It holds Maravai Lifesciences Holdings’s shares valued at 3M.
---
Maravai Lifesciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (20.09% Upside)
$11.00 (20.09% Upside)
Blogger Sentiment
Neutral
MRVI Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 468.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.66%
12-Months-Change
Fundamentals
Return on Equity
-27.59%
Trailing 12-Months
Asset Growth
-36.07%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
---
MRVI Company Deck
---
MRVI Earnings Call
Q2 2024
0:00 / 0:00
---
MRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
---
MRVI Stock 12 Month Forecast
Average Price Target
$11.00
▲(20.09% Upside)
Technical Analysis
Best Analysts Covering MRVI
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
-2.41%
reiterated a buy rating last month
Copying Conor McNamara's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of -2.41% per trade.
---